Jason Muhitch

PhD

Specializing In:

Radiation-induced anti-tumor immunity Tumor-conditioned monocyte/macrophage plasticity Renal cell carcinoma Molecular determinants of intratumoral T cell infiltration

Research Interests:

Dynamic imaging of T cell function Combinatorial approaches to improve immunotherapy

About Jason Muhitch

Positions

Roswell Park Comprehensive Cancer Center
  • Associate Professor of Oncology
  • Co-Chair, Genitourinary Translational Research Group (TRG)
  • Deputy Director, Graduate Studies
  • Department of Immunology

Background

Education and Training:

  • 2013 - PhD - Biological Sciences, State University of New York at Buffalo

Professional Memberships:

  • The American Association of Immunologists
  • Radiation Research Society
  • American Urological Association
  • Society for Basic Urologic Research

Honors & Awards:

  • 2021 - Chair, Radiation and Anti-tumor Immunity Session, Radiation Research Society
  • 2019 - Chair, Understanding Immune Responses to Cancer, Upstate NY Immunology Conference
  • 2018 - Early Career Investigator Travel Award, Radiation Research Society
  • 2018 - Chair, Cell Therapies Session, Translational Research Cancer Centers Consortium
  • 2014 - Best Poster, Northeastern Section of the American Urological Association
  • 2013 - Travel award, Midwest Melanoma Partnership
  • 2012 - The American Association of Immunologists Young Investigators Award, Upstate New York Immunology Conference
  • 2012 - Junior Investigator Award, Translational Research Cancer Centers Consortium Meeting
  • 2011 - 1st Place New Investigator Travel Award, Society for Thermal Medicine

Research

Research Overview:

The goal of my laboratory is to elucidate the molecular mechanisms that limit renal cell carcinoma patient responses to immunotherapy. The laboratory’s translational studies are concentrated on enhancing anti-tumor immunity through improved myeloid cell function and cytolytic T cell activity within renal cell carcinoma. Our laboratory’s findings from a pilot trial in metastatic renal cell carcinoma combining high-dose radiation of kidney tumors with surgical resection, provide a glimpse into the immune activating effects of radiation in human cancer. The laboratory’s most recent studies performed in collaboration with Dr. Scott Abrams shed light on the role key transcription factors at play in macrophage behavior and patient outcome.

View the Muhitch Lab


Publications

Full Publications list on PubMed

Chow J, Khan A, Gaudieri M, Conway A, Soh K, Repasky EA, Schwaab T, Wallace PK, Abrams SI, Singh AK, Muhitch JB. Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2023; 11:e006392.

Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proceedings of the National Academy of Sciences. 2020; Sep 22; 117(38): 23721-23729.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SO. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2019; 7: 155.

Singh AK, Winslow T, Habiby Kermany M, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi KO, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB. A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clinical Cancer Research. 2017; 23: 5055-5065.

Battaglia S and Muhitch JB. Unmasking targets of antitumor immunity via high-throughput antigen profiling. Current Opinion in Biotechnology. 2016; 42: 92-97.